康泰生物：Sabin株脊髓灰质炎灭活疫苗（Vero细胞）获批上市

Core Viewpoint - Kangtai Biological (300601.SZ) announced that its wholly-owned subsidiary, Beijing Minhai Biological Technology Co., Ltd., received a drug registration certificate from the National Medical Products Administration for the Sabin strain inactivated poliovirus vaccine (Vero cells), which is approved for market launch to prevent acute infectious diseases caused by poliovirus [1] Company Summary - The approval of the vaccine will further enrich the company's product lineup and enhance its core competitiveness [1] - However, the timeline for the product's market launch has certain uncertainties, prompting investors to make cautious decisions and be aware of investment risks [1]